Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 11/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733606 | 0.74 | IDO1 (0.42) | IDO1ADRA2AALDH1A1POLBRXFP1 | |
| SCHEMBL7517293 | 0.74 | IDO1 (0.41) | IDO1PARP1PIM1MAP4K4CSF1R | |
| SCHEMBL21437991 | 0.68 | HSD17B10 (0.44) | IDO1PARP1ALDH1A1POLBRXFP1 | |
| SCHEMBL1374153 | 0.65 | KDM4A (0.37) | IDO1CDK5 | |
| SCHEMBL6998276 | 0.65 | NPC1 (0.36) | IDO1GSK3BCDK5ALDH1A1MEN1 | |
| SCHEMBL27513844 | 0.64 | MEN1 (0.33) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5375138 | 0.64 | — | — | |
| SCHEMBL17634049 | 0.64 | MEN1 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL28413211 | 0.61 | IDO1 (0.53) | IDO1PIM1ALDH1A1POLBMEN1 | |
| Hydrochloric Acid SCHEMBL30898465 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577377-B2 | Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180118695-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-05-03 | — | — | US | disclosed |
| US-9624178-B2 | Substituted cyclopenta pyrimidine bicyclic compounds having antitmitotic and/or antitumor activity methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2014-10-09 | — | — | US | disclosed |
| CN-100398524-C | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists | ROCHE PALO ALTO LLC (CH) | 2008-07-02 | — | — | CN | disclosed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| US-7138398-B2 | Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-21 | — | — | US | disclosed |
| CN-1835931-A | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists | ROCHE PALO ALTO LLC (CH) | 2006-09-20 | — | — | CN | disclosed |
| EP-1656354-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| EP-1131302-B1 | SUBSTITUTED 4-AMINO-2-ARYL-CYCLOPENTA [D]PYRIMIDINES, THEIR PRODUCTION AND USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005014557-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20040048850-A1 | Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-03-11 | — | — | US | disclosed |
| US-6627628-B1 | Cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are suitable for | AVENTIS PHARMA DEUTSCHLAND, GMBH (DE) | 2003-09-30 | — | — | US | disclosed |
| EP-1131302-A1 | SUBSTITUTED 4-AMINO-2-ARYL-CYCLOPENTA D]PYRIMIDINES, THEIR PRODUCTION AND USE AND PHARMACEUTICALREPARATIONS CONTAINING SAME | Aventis Pharma Deutschland GmbH (DE) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031047-A1 | SUBSTITUTED 4-AMINO-2-ARYL-CYCLOPENTA[D]PYRIMIDINES, THEIR PRODUCTION AND USE AND PHARMACEUTICALREPARATIONS CONTAINING SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577377-B2 | Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCG2, ABCB1, ABCC1 | IDO1 4123/4885PARP1 518/4885PIM1 1692/4885 |
| US-20040048850-A1 | Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them | PDE3A, PDE2A, NPR1 | IDO1 2636/4885PARP1 1195/4885PIM1 1906/4885 |
| US-20180118695-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCB1, ABCC1 | IDO1 4123/4885PARP1 518/4885PIM1 1692/4885 |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | ABCC1, ABCG2, ABCB1 | IDO1 4169/4885PARP1 760/4885PIM1 2015/4885 |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | CRHR1, AVPR2, CRHR2 | IDO1 1047/4885PARP1 3416/4885PIM1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.